Table 2.
Distribution of the study population by lipid-lowering therapy (LLT) intensity initiated during hospitalization, at 6-month and 12-month follow-up, and low-density lipoprotein cholesterol (LDL-C) goal attainment at 6-month and 12-month follow-up (1 January 2010–31 December 2015)
| LDL-C (mmol/L) | |||||||
|---|---|---|---|---|---|---|---|
| 6-month follow-upd (N = 2242) | 12-month follow-upe (N = 1547) | ||||||
| LLT | Total | < 1.8 | ≥1.8 | Total | < 1.8 | ≥1.8 | |
| Before or during index hospitalizationa | 2242 | 912 (40.7) | 1330 (59.3) | 1547 | 604 (39.0) | 943 (61.0) | |
| None | 173 (7.7) | 34 (19.7) | 139 (80.3) | 122 (7.9) | 25 (20.5) | 97 (79.5) | |
| Moderateb | 1888 (84.2) | 801 (42.4) | 1087 (57.6) | 1282 (82.9) | 519 (40.5) | 763 (59.5) | |
| Intensivec | 181 (8.1) | 77 (42.5) | 104 (57.5) | 143 (9.2) | 60 (42.0) | 83 (58.0) | |
| LLT | |||||||
| Before or during index hospitalizationa | 6-month follow-up | ||||||
| None | None | 120/173 (69.4) | 17/120 (14.2) | 103/120 (85.8) | 89/122 (73.0) | 11/89 12.4) | 78/89 (87.6) |
| Moderateb | 46/173 (26.6) | < 15 | < 35 | 28/122 (23.0) | < 15 | < 20 | |
| Intensivec |
7/173 (4.0) |
< 7 | < 7 | 5/122 (4.1) | < 5 | < 5 | |
| Yes | None | 123/2069 (5.9) | 41/123 (33.3) | 82/123 (66.7) | 72/1425 (5.1) | 19/72 (26.4) | 53/72 (73.6) |
| Moderateb | 1501/2069 (72.5) | 644/1501 (42.9) | 857/1501 (57.1) | 1041/1425 (73.1) | 425/1041 (40.8) | 616/1041 (59.2) | |
| Intensivec | 445/2069 (21.5) | 193/445 (43.4) | 252/445 (56.6) | 312/1425 (21.9) | 135/312 (43.3) | 177/312 (56.7) | |
| LLT | |||||||
| 6-month follow-up | 12-month follow-up | ||||||
| None | None | – | – | – | 113/161 (70.2) | 15/113 (13.3) | 98/113 (86.7) |
| Moderateb | – | – | – | 38/161 (23.6) | < 15 | < 30 | |
| Intensivec | – | – | – | 10/161 (6.2) | < 5 | < 10 | |
| Yes | None | – | – | – | 66/1386 (4.8) | 13/66 (19.7) | 53/66 (80.3) |
| Moderateb | – | – | – | 871/1386 (62.8) | 347/871 (39.8) | 524/871 (60.2) | |
| Intensivec | – | – | – | 449/1386 (32.4) | 214/449 (47.7) | 235/449 (52.3) | |
a LLT initiated before or during index hospitalization: LLT redeemed −180 before admission to 30 days
after discharge
b Patients who are treated with LLT, but who are not eligible for the group of “intensive treatment” or “no LLT” treatment
c Intensive LLT is defined by 1) A minimum of 2 prescription redemptions of one combination drug; OR 2) A minimum of 2 statins prescription redemptions; OR 3) A minimum of 2 statin prescription redemptions and one ezetimibe prescription redemption; OR 4) A minimum of 2 statin prescription redemptions and one other non-statin (i.e. not ezetimibe) prescription redemption
d LDL-C at 6-month follow-up: LDL-C between discharge and 180 days post discharge from hospital with ACS
e LDL-C at 12-month follow-up: LDL-C between 181 and 365-days post discharge from hospital with ACS